Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Blood (2023) 142 (Supplement 1): 469.

https://doi.org/10.1182/blood-2023-182177

Published: 2023

Journal Articles

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Blood (2023) 142 (Supplement 1): 2159.

https://doi.org/10.1182/blood-2023-187433

Published: 2023

Journal Articles

Azacitidine, Venetoclax and Allogeneic NK Cells in Newly Diagnosed Acute Myeloid Leukemia (ADVENT-AML): An Investigator-Initiated Multicenter Phase Ib Trial

Abhishek Maiti, Muharrem Muftuoglu, James J. Ignatz-Hoover, Courtney D. DiNardo, Farhad Ravandi, Michael Andreeff, Lianchun Xiao, Xuelin Huang, Keyur P. Patel, Jason B Litten, Eliot Bourk, Stephanie Astrow, Hagop M. Kantarjian, Ben K. Tomlinson, Naval Daver, David Wald

Blood (2023) 142 (Supplement 1): 4863.

https://doi.org/10.1182/blood-2023-182885

Published: 2023

Journal Articles

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Blood (2023) 142 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2023-189040

Published: 2023

Journal Articles

Final Results of a Phase I/II Trial of Carfilzomib + R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL)

Brian T. Hill, Pallawi Torka, Francisco J. Hernandez-Ilizaliturri, Robert M. Dean, Deepa Jagadeesh, Kasra Karamlou, Chieh-Lin Fu, Allison Winter, Ethan Krauspe, Jonathan Zhou, Taylor R. Brooks, Merve Kacar, Ben K. Tomlinson, Brenda W Cooper, Hong Li, Xuefei Jia, Yanwen Chen, Jenna Thomas, Paolo F. Caimi

Blood (2023) 142 (Supplement 1): 3087.

https://doi.org/10.1182/blood-2023-173943

Published: 2023

Journal Articles

A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation

Blood (2023) 142 (Supplement 1): 5953.

https://doi.org/10.1182/blood-2023-181151

Published: 2023

Journal Articles

Use of a Fitness Tracking Device to Monitor Physical Activity and Sleep Patterns during Hospitalization for Hematopoietic Stem Cell Transplant. Results of a Prospective Observational Study

Najla H El Jurdi, MD, Mathew J Cotton, MS, Raisa Pinto, MD, Erin Galloway, RN BSN, Samantha Kolke, RN, BSN, Brenda W. Cooper, MD, Ben K. Tomlinson, MD, Leland Metheny, MD, Ehsan Malek, MD, Nora Nock, PhD, Merle Kolk, Richard Lee, Marcos De Lima, MD, Paolo Caimi, MD

Blood (2017) 130 (Supplement 1): 3446.

https://doi.org/10.1182/blood.V130.Suppl_1.3446.3446

Published: 2017

Journal Articles

Pilot Use of a Novel DNA Methytransferase -1 (DNMT1) Flow Cytometric Pharmacodynamic Assay to Evaluate Response to Low-Dose Azacitidine Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Hematopoietic Cell Transplantation

Najla H El Jurdi, MD, Masumi Ueda, MD MA, BA, Philip Woost, PhD, Hillard M Lazarus, MD, Paolo Caimi, MD, Brenda W. Cooper, MD, Richard Creger, PhD, Jane A. Little, MD, Linda Baer, MSN, NP-C, AOCNP, Lauren Brister, MSN, NP-C, AOCNP, Ehsan Malek, MD, Leland Metheny, MD, Folashade Otegbeye, MBBChir, MPH, Ben K. Tomlinson, MD, Basem M. William, MRCP,MD, James Jacobberger, PhD, Marcos De Lima, MD

Blood (2017) 130 (Supplement 1): 5503.

https://doi.org/10.1182/blood.V130.Suppl_1.5503.5503

Published: 2017

Journal Articles

Optimizing Autologous Stem Cell Transplant for High-Risk Patients with Plasma Cell Dyscrasias

Naveed Ali, MD, Brenda W. Cooper, MD, Merle Kolk, Richard Creger, PhD, Gina Hoffman, Hillard M Lazarus, MD, Ben K. Tomlinson, MD, Paolo Caimi, MD, Leland Metheny, MD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2017) 130 (Supplement 1): 5656.

https://doi.org/10.1182/blood.V130.Suppl_1.5656.5656

Published: 2017

Journal Articles

Prognostic Impact of Morphological Cellularity in Early Assessment Bone Marrow Biopsy after 7+3 Induction in Patients with Acute Myeloid Leukemia

Fahrettin Covut, MD, Divya Gupta, MD, Raisa Pinto, MD, Nina Dambrosio, CNP, Najla H El Jurdi, MD, Masumi Ueda, MD MA, BA, Leland Metheny, MD, Brenda W. Cooper, MD, Paolo Caimi, MD, Ehsan Malek, MD, Folashade Otegbeye, MBBChir, MPH, Marcos De Lima, MD, Ben K. Tomlinson, MD

Blood (2017) 130 (Supplement 1): 1314.

https://doi.org/10.1182/blood.V130.Suppl_1.1314.1314

Published: 2017

Journal Articles

Treatment of Secondary Post-Transplant Engraftment Failure with Donor CD34+ Enriched, T-Cell Depleted Peripheral Blood Stem Cells Isolated By the Clinimacs® System

Paolo Caimi, MD, Jane Reese, Merle Kolk, Robert Fox, Kari Eckmeyer, RN, Erin Galloway, RN BSN, Gina Hoffman, Ehsan Malek, MD, Leland Metheny, MD, Ben K. Tomlinson, MD, Richard Creger, PhD, Brenda W. Cooper, MD, Hillard M Lazarus, MD, Marcos de Lima, MD

Blood (2017) 130 (Supplement 1): 1956.

https://doi.org/10.1182/blood.V130.Suppl_1.1956.1956

Published: 2017

Journal Articles

Central Nervous System Relapse in Diffuse Large B Cell Lymphoma—Predictors at Diagnosis

Sabarish Ayyappan, MBBS, Fahrettin Covut, MD, Dhivya Prabhakar, MD, Vinita Gupta, MD, Ehsan Malek, MD, Leland Metheny, MD, Ben K. Tomlinson, MD, Richard Creger, PhD, Brenda W. Cooper, MD, Hillard M Lazarus, MD, Marcos de Lima, MD, Paolo Caimi, MD

Blood (2017) 130 (Supplement 1): 2842.

https://doi.org/10.1182/blood.V130.Suppl_1.2842.2842

Published: 2017

Journal Articles

A Phase II Study of Midostaurin and 5-Azacitidine for Elderly Patients with Acute Myeloid Leukemia

Molly M Gallogly, MDPhD, Ben K. Tomlinson, MD, Pam Bunner, MT, CCRC, Paolo Caimi, MD, Michael Craig, MD, Marcos de Lima, MD, Stanton L. Gerson, MD, Donna Kane, RN, MSN, Hillard M Lazarus, MD, Mark J. Levis, MD, Ehsan Malek, MD, Jane A. Little, MD, Crystal Street, MT, CCRC, Willem J. van Heeckeren, MD PhD, William Tse, MD, Brenda W. Cooper, MD

Blood (2017) 130 (Supplement 1): 1332.

https://doi.org/10.1182/blood.V130.Suppl_1.1332.1332

Published: 2017

Journal Articles

A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML)

Blood (2016) 128 (22): 4065.

https://doi.org/10.1182/blood.V128.22.4065.4065

Published: 2016

Journal Articles

Low Dose Antithymocyte Globulin (ATG) for Graft-Versus-Host Disease (GVHD) Prophylaxis

Anand Tandra, MD, Leland Metheny, MD, David Yao, MD PhD, Paolo F. Caimi, MD, Lauren Brister, CNP, Brenda Cooper, MD, Hillard M. Lazarus, MD, Ben K. Tomlinson, MD, Ehsan Malek, MD, Fahrettin Covut, MD, Raisa Pinto, MD, Marcos deLima, MD

Blood (2016) 128 (22): 5788.

https://doi.org/10.1182/blood.V128.22.5788.5788

Published: 2016

Journal Articles

Cardiovascular Toxicity after Therapy for Diffuse Large B Cell Lymphoma Occurs Early and Results in Decreased Overall Survival.

Sabarish Ram Ayyappan, MBBS, Akiva Diamond, MD, Vinita Gupta, MD, Brenda Cooper, MD, Ben K. Tomlinson, MD, Ehsan Malek, MD, Leland Metheny, MD, Hillard M. Lazarus, MD, Stanton L. Gerson, MD, Marcos De Lima, MD, Paolo F. Caimi, MD

Blood (2016) 128 (22): 105.

https://doi.org/10.1182/blood.V128.22.105.105

Published: 2016

Journal Articles

Venous Thromboembolic Events in Diffuse Large B Cell Lymphoma Patients: Risk Factors and Outcomes

Sabarish Ram Ayyappan, MBBS, Vinita Gupta, MD, Akiva Diamond, MD, Brenda Cooper, MD, Ben K. Tomlinson, MD, Ehsan Malek, MD, Leland Metheny, MD, Hillard M. Lazarus, MD, Stanton L. Gerson, MD, Marcos De Lima, MD, Paolo F. Caimi, MD

Blood (2016) 128 (22): 3611.

https://doi.org/10.1182/blood.V128.22.3611.3611

Published: 2016

Journal Articles

Treatment of Diffuse Large Cell Lymphoma (DLBCL) Patients Older Than 75 Years: Higher Mortality and Risk of Complications without Increased Risk of Relapse after Treatment

Akiva Diamond, MD, Sabarish Ram Ayyappan, MBBS, Raisa Pinto, MD, Ehsan Malek, MD, Ben K. Tomlinson, MD, Leland Metheny, MD, Brenda Cooper, MD, Stanton L. Gerson, MD, Hillard M. Lazarus, MD, Marcos De Lima, MD, Paolo F. Caimi, MD

Blood (2016) 128 (22): 1863.

https://doi.org/10.1182/blood.V128.22.1863.1863

Published: 2016

NARROW

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Azacitidine, Venetoclax and Allogeneic NK Cells in Newly Diagnosed Acute Myeloid Leukemia (ADVENT-AML): An Investigator-Initiated Multicenter Phase Ib Trial

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Final Results of a Phase I/II Trial of Carfilzomib + R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation

Use of a Fitness Tracking Device to Monitor Physical Activity and Sleep Patterns during Hospitalization for Hematopoietic Stem Cell Transplant. Results of a Prospective Observational Study

Pilot Use of a Novel DNA Methytransferase -1 (DNMT1) Flow Cytometric Pharmacodynamic Assay to Evaluate Response to Low-Dose Azacitidine Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Hematopoietic Cell Transplantation

Optimizing Autologous Stem Cell Transplant for High-Risk Patients with Plasma Cell Dyscrasias

Prognostic Impact of Morphological Cellularity in Early Assessment Bone Marrow Biopsy after 7+3 Induction in Patients with Acute Myeloid Leukemia

Treatment of Secondary Post-Transplant Engraftment Failure with Donor CD34+ Enriched, T-Cell Depleted Peripheral Blood Stem Cells Isolated By the Clinimacs® System

Central Nervous System Relapse in Diffuse Large B Cell Lymphoma—Predictors at Diagnosis

A Phase II Study of Midostaurin and 5-Azacitidine for Elderly Patients with Acute Myeloid Leukemia

A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML)

Low Dose Antithymocyte Globulin (ATG) for Graft-Versus-Host Disease (GVHD) Prophylaxis

Cardiovascular Toxicity after Therapy for Diffuse Large B Cell Lymphoma Occurs Early and Results in Decreased Overall Survival.

Venous Thromboembolic Events in Diffuse Large B Cell Lymphoma Patients: Risk Factors and Outcomes

Treatment of Diffuse Large Cell Lymphoma (DLBCL) Patients Older Than 75 Years: Higher Mortality and Risk of Complications without Increased Risk of Relapse after Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only